Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161


Safety of indacaterol in the treatment of patients with COPD.

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:477-92. doi: 10.2147/COPD.S23816. Epub 2011 Sep 22.


Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.

Bleecker ER, Siler T, Owen R, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:431-8. doi: 10.2147/COPD.S21073. Epub 2011 Aug 18.


Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.


Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.

Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.

Lung. 2013 Apr;191(2):135-46. doi: 10.1007/s00408-012-9444-2. Epub 2013 Jan 10. Review.


Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.

Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:215-28. doi: 10.2147/COPD.S51592. eCollection 2014.


Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.

Kerwin EM, Williams J.

Ther Adv Respir Dis. 2013 Feb;7(1):25-37. doi: 10.1177/1753465812470018. Epub 2013 Jan 7. Review.


Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.

Respir Med. 2013 Feb;107(2):223-32. doi: 10.1016/j.rmed.2012.10.022. Epub 2012 Dec 6.


Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

Worth H, Chung KF, Felser JM, Hu H, Rueegg P.

Respir Med. 2011 Apr;105(4):571-9. doi: 10.1016/j.rmed.2010.11.027. Epub 2011 Jan 11.


Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.

Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435.


Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.

McKeage K.

Drugs. 2012 Mar 5;72(4):543-63. doi: 10.2165/11208490-000000000-00000. Review.


Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.

Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ.

Cochrane Database Syst Rev. 2015 Jan 10;1:CD010139. doi: 10.1002/14651858.CD010139.pub2. Review.


Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; INTENSITY study investigators.

Eur Respir J. 2011 Oct;38(4):797-803. doi: 10.1183/09031936.00191810. Epub 2011 May 26.


Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators.

Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62. doi: 10.1164/rccm.200910-1500OC. Epub 2010 May 12.


Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.

Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2013;8:501-8. doi: 10.2147/COPD.S49615. Epub 2013 Oct 17. Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:85. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.


Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B; INTEGRAL Study Investigators.

Pulm Pharmacol Ther. 2011 Feb;24(1):162-8. doi: 10.1016/j.pupt.2010.06.005. Epub 2010 Jul 7.


Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.

Pulm Pharmacol Ther. 2007;20(6):740-9. Epub 2006 Sep 30.


Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.

Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2016 Oct 11;11:2543-2551. eCollection 2016. Erratum in: Int J Chron Obstruct Pulmon Dis. 2017 Jan 10;12 :231.


Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.

Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, Lim SY, Shim JJ, Lee YC, Kim YS, Oh YM, Kim S, Yoo CG.

Int J Chron Obstruct Pulmon Dis. 2017 May 29;12:1589-1596. doi: 10.2147/COPD.S128750. eCollection 2017.

Supplemental Content

Support Center